Crestline Management’s Bristol-Myers Squibb BMY Stock Holding History

Crestline Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,559	Closed	-$767K	–	82
2024 Q4	$767K	Sell	13,559 -13,520	-50%	-$755K	0.03%	462
2024 Q3	$1.4M	Buy	+27,079	New	+$1.27M	0.07%	232
2019 Q3	–	Sell	-77,000	Closed	-$3.49M	–	83
2019 Q2	$3.49M	Buy	+77,000	New	+$3.59M	0.47%	34
2018 Q3	–	Sell	-64,224	Closed	-$3.55M	–	159
2018 Q2	$3.55M	Buy	64,224 +18,940	+42%	+$1.02M	0.37%	65
2018 Q1	$2.86M	Sell	45,284 -7,005	-13%	-$451K	0.36%	38
2017 Q4	$3.2M	Buy	52,289 +11,889	+29%	+$744K	0.33%	26
2017 Q3	$2.58M	Buy	+40,400	New	+$2.36M	0.36%	46

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crestline Management's BMY Position: Q1 2025 in Review

Crestline Management sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 13,559 shares — an estimated $767K sold.

Crestline Management first reported a position in BMY in Q3 2017 and held it in 7 quarters. The position peaked at $3.55M in Q2 2018. 2,477 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

Crestline Management reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 13,559 Bristol-Myers Squibb shares in Q1 2025, an estimated $767K.
Crestline Management first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 7 quarters.
Crestline Management's Bristol-Myers Squibb position peaked at $3.55M in Q2 2018.
2,477 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.